4:32 PM
Sep 14, 2017
 |  BioCentury  |  Finance

Tech attraction

Why tech VCs participated in Sophia Genetics’ $30 million series D round

Sophia Genetics S.A. aims to expand use of its genome analysis platform in the U.S. with the backing of tech VCs -- who believe the sequencing and diagnostics space is now mature enough for IT investors to jump in.

On Sept. 13, Sophia nearly doubled its total money raised with a $30 million series D round led by Balderton Capital. Fellow new investor 360 Capital Partners and existing investors Invoke Capital and Alychlo also participated. Sophia had raised a total of $31.6 million in the previous three rounds...

Read the full 423 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >